Berlin, Germany

Advanced Sleep Research

Obstructive Sleep Apnea

Sleep Apnea Syndromes

Apnea

Obesity

Chronic Obstructive Pulmonary Disease

Syndrome

Lung Diseases

Respiration Disorders

Respiratory Signs and Symptoms

Overweight

ACT-541468

Orforglipron

Tirzepatide

LY3298176

Idorsia Pharmaceuticals

Lilly

ImThera Medical

condition

allSponsorName

gender

Male

Female

overallStatus

Recruiting

Not yet recruiting

Active, not recruiting

Enrolling by invitation

Completed

Terminated

Withdrawn

Suspended

Unknown

type

Interventional

Observational

Expanded Access

phase

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Not Applicable

funderTypes

Industry

Other U.S. Federal agency

All others

ageGroup

Child (birth-17)

Adult (18-64)

Older Adult (65+)

Study GZRA is a master protocol that will support 2 independent studies, GZ01 and GZ02. Participants will be assigned to the appropriate study prior to randomization. The purpose of the studies is to evaluate the efficacy and safety of orforglipron in participants who have moderate-to-severe OSA and obesity or overweight. Study GZ01 will include participants who are unable or are unwilling to use PAP therapy. Study GZ02 will include participants who are on PAP therapy for at least 3 months at time of screening and plan to continue PAP therapy during the study.

A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight

Advanced Sleep Research | Berlin, Germany

Site insights

Work at this site?

Active trials

A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight (ATTAIN-OSA)

Trial sponsors